News Powered By:
– a collaborative partner.
Susan Salome : June 21, 2017 12:30 pm : Carolinas HealthCare System, Centerwatch, Cerner, Global News, Study Conduct
Cerner, a global leader in health care technology, has announced Carolinas HealthCare System (CHS) has chosen Cerner’s HealtheIntentSM population health management platform to coordinate and manage care for its more than 12 million patient interactions each year across its facilities and clinically integrated network, Carolinas Physician Alliance (CPA). CHS will continue to use the Cerner Millennium® […]
The post Cerner’s Population Health Management Platform chosen by Cerner to coordinate and manage care appeared first on CenterWatch News Online.
Susan Salome : June 21, 2017 11:00 am : Centerwatch, Global News, MatrixCare, R&D Trends, SigmaCare
MatrixCare has announced that it has acquired SigmaCare, a leading EHR vendor for the long-term, post-acute care market, based in Manhattan. MatrixCare is the number one ranked and largest provider of EHR and related solutions to the U.S. senior care market, serving over 12,000 facility-based care settings and over 2,000 home care agency offices throughout […]
Susan Salome : June 21, 2017 10:30 am : Centerwatch, Clinical Intelligence, Global News, Melinta Therapeutics
Melinta Therapeutics, a privately held company focused on discovering, developing, and commercializing novel antibiotics to treat serious bacterial infections, has announced that the U.S. Food and Drug Administration (FDA) has approved Baxdela™ (delafloxacin), indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria. Baxdela is a […]
The post Melinta announces FDA approval of Baxdela (delafloxacin) appeared first on CenterWatch News Online.
Sarepta Therapeutics and Genethon announce collaboration for the treatment of Duchenne muscular dystrophy
Susan Salome : June 21, 2017 10:00 am : Centerwatch, Genethon, Global News, R&D Trends, Sarepta Therapeutics
Sarepta Therapeutics, Inc., a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, and Genethon, a non-profit R&D organization dedicated to the development of biotherapies for orphan genetic diseases from research to clinical validation, have signed a gene therapy research collaboration to jointly […]
Susan Salome : June 21, 2017 9:30 am : Centerwatch, Clinical Intelligence, Global News, Helsinn Group
Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, has announced that data showing the non-inferiority of NEPA (netupitant/palonestron) versus a 3-day oral aprepitant (APR)/granisetron (GRAN) regimen, have been accepted for presentation at the upcoming Multinational Association of Supportive Care in Cancer (MASCC/ISOO) Congress, on June 22-24 2017. NEPA is the first […]
The post Helsinn Group announces presentation of Phase III data in NEPA at the MASCC/ISOO Congress appeared first on CenterWatch News Online.